194 related articles for article (PubMed ID: 31548813)
1.
Harlos C; Metser U; Poon R; MacCrostie P; Mason W
Curr Oncol; 2019 Aug; 26(4):e458-e465. PubMed ID: 31548813
[TBL] [Abstract][Full Text] [Related]
2. Imaging Workup of Suspected Classical Paraneoplastic Neurological Syndromes: A Systematic Review and Retrospective Analysis of
Sundermann B; Schröder JB; Warnecke T; Heindel W; Schäfers M; Weckesser M; Buerke B
Acad Radiol; 2017 Oct; 24(10):1195-1202. PubMed ID: 28551401
[TBL] [Abstract][Full Text] [Related]
3. Occult malignancy in patients with suspected paraneoplastic neurologic syndromes: value of positron emission tomography in diagnosis.
Patel RR; Subramaniam RM; Mandrekar JN; Hammack JE; Lowe VJ; Jett JR
Mayo Clin Proc; 2008 Aug; 83(8):917-22. PubMed ID: 18674476
[TBL] [Abstract][Full Text] [Related]
4.
García Vicente AM; Delgado-Bolton RC; Amo-Salas M; López-Fidalgo J; Caresia Aróztegui AP; García Garzón JR; Orcajo Rincón J; García Velloso MJ; de Arcocha Torres M; Alvárez Ruíz S;
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1575-1587. PubMed ID: 28550611
[TBL] [Abstract][Full Text] [Related]
5. Whole-Body
Sheikhbahaei S; Marcus CV; Fragomeni RS; Rowe SP; Javadi MS; Solnes LB
J Nucl Med; 2017 Jul; 58(7):1031-1036. PubMed ID: 27980049
[TBL] [Abstract][Full Text] [Related]
6. Accuracy of FDG-PET/CT and paraneoplastic antibodies in diagnosing cancer in paraneoplastic neurological syndromes.
Vatankulu B; Yilmaz Aksoy S; Asa S; Sager S; Sayman HB; Halac M; Sonmezoglu K
Rev Esp Med Nucl Imagen Mol; 2016; 35(1):17-21. PubMed ID: 26260889
[TBL] [Abstract][Full Text] [Related]
7. Utility of F-18 FDG PET/CT in screening for paraneoplastic neurological syndromes.
Matsuhisa A; Toriihara A; Kubota K; Makino T; Mizusawa H; Shibuya H
Clin Nucl Med; 2012 Jan; 37(1):39-43. PubMed ID: 22157026
[TBL] [Abstract][Full Text] [Related]
8. [(18)F-FDG PET/CT in the evaluation of patients suspected of paraneoplastic neurological syndrome].
García Vicente AM; Vega Caicedo CH; Mondéjar Solís R; de Ayala Fernández JÁ; Garrido Robles JA; Pena Pardo FJ; Muñoz Pasadas M; Del Saz Saucedo P; Jiménez Londoño GA; León Martín A; Soriano Castrejón Á
Rev Esp Med Nucl Imagen Mol; 2015; 34(4):236-43. PubMed ID: 25864422
[TBL] [Abstract][Full Text] [Related]
9. 18F-FDG-PET/CT in the diagnosis of paraneoplastic neurological syndromes: a retrospective analysis.
Bannas P; Weber C; Derlin T; Lambert J; Leypoldt F; Adam G; Mester J; Klutmann S
Eur Radiol; 2010 Apr; 20(4):923-30. PubMed ID: 19789881
[TBL] [Abstract][Full Text] [Related]
10. Detection of underlying malignancy in patients with paraneoplastic neurological syndromes: comparison of 18F-FDG PET/CT and contrast-enhanced CT.
Schramm N; Rominger A; Schmidt C; Morelli JN; Schmid-Tannwald C; Meinel FG; Reiser MF; Rist C
Eur J Nucl Med Mol Imaging; 2013 Jul; 40(7):1014-24. PubMed ID: 23503574
[TBL] [Abstract][Full Text] [Related]
11. FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes.
Younes-Mhenni S; Janier MF; Cinotti L; Antoine JC; Tronc F; Cottin V; Ternamian PJ; Trouillas P; Honnorat J
Brain; 2004 Oct; 127(Pt 10):2331-8. PubMed ID: 15361417
[TBL] [Abstract][Full Text] [Related]
12. Clinical value of FDG-PET/CT in suspected paraneoplastic syndromes: a retrospective analysis of 137 patients.
Kristensen SB; Hess S; Petersen H; Høilund-Carlsen PF
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):2056-63. PubMed ID: 26194717
[TBL] [Abstract][Full Text] [Related]
13. Whole-body
Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T
Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
[TBL] [Abstract][Full Text] [Related]
14. Semiquantitative analysis of brain metabolism in patients with paraneoplastic neurologic syndromes.
Clapp AJ; Hunt CH; Johnson GB; Peller PJ
Clin Nucl Med; 2013 Apr; 38(4):241-7. PubMed ID: 23429394
[TBL] [Abstract][Full Text] [Related]
15. Role of
Piccardo A; Trimboli P; Puntoni M; Foppiani L; Treglia G; Naseri M; Bottoni GL; Massollo M; Sola S; Ferrarazzo G; Bruzzone M; Catrambone U; Arlandini A; Paone G; Ceriani L; Cabria M; Giovanella L
Thyroid; 2019 Apr; 29(4):549-556. PubMed ID: 30864903
[TBL] [Abstract][Full Text] [Related]
16. Role of FDG-PET in the clinical management of paraneoplastic neurological syndrome: detection of the underlying malignancy and the brain PET-MRI correlates.
Basu S; Alavi A
Mol Imaging Biol; 2008; 10(3):131-7. PubMed ID: 18297363
[TBL] [Abstract][Full Text] [Related]
17. 18F-fluorodeoxyglucose positron emission tomography-computed tomography for suspected recurrent papillary thyroid cancer: early experience at Sunnybrook Health Sciences Centre.
Dahele M; Ung YC; Ehrlich L; Silverberg J; Balogh J; Wong CS
J Otolaryngol Head Neck Surg; 2008 Oct; 37(5):712-7. PubMed ID: 19128681
[TBL] [Abstract][Full Text] [Related]
18. 18F-FDG PET-CT in the evaluation of paraneoplastic syndromes: experience at a regional oncology centre.
Vaidyanathan S; Pennington C; Ng CY; Poon FW; Han S
Nucl Med Commun; 2012 Aug; 33(8):872-80. PubMed ID: 22669052
[TBL] [Abstract][Full Text] [Related]
19. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
[TBL] [Abstract][Full Text] [Related]
20. PET scan in clinically suspected paraneoplastic neurological syndromes: a 6-year prospective study in a regional neuroscience unit.
Hadjivassiliou M; Alder SJ; Van Beek EJ; Hanney MB; Lorenz E; Rao DG; Sharrack B; Tindale WB
Acta Neurol Scand; 2009 Mar; 119(3):186-93. PubMed ID: 18855873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
